References
- Meador KJ, Baker GA, Finnell RH et al.; NEAD study group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology67(3), 407–412 (2006).
- Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol.4, 781–786 (2005).
- Harden Cl, Meador KJ, Pennell PB et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology73(2), 133–141 (2009).
- Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs67(18), 2727–2746 (2007).
- Mohanraj R, Brodie MJ. Pharmacologic outcomes in newly diagnosed epilepsy. Epilepsy Behav.6(3), 382–287 (2005).
- Tatum WO. The use of antiepileptic drugs in pregnancy. Expert Rev. Neurother.6(7), 1077–1086 (2006).
- Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology61(6 Suppl. 2), S35–S42 (2003).
- Meador KJ, Baker GA, Browning N; NEAD study group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med.360(16), 1597–1605 (2009).
- Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst. Rev.3, CD004848 (2004).